A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)
Latest Information Update: 21 Sep 2022
At a glance
- Drugs EDP 514 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Enanta Pharmaceuticals
Most Recent Events
- 26 Jun 2022 Results safety, pharmacokinetic (PK) and antiviral activity from a phase 1b study of multiple ascending doses (MAD), presented at The International Liver Congress 2022.
- 06 Jan 2022 Status changed from recruiting to completed.
- 15 Nov 2021 Results for the 200mg and 400mg cohorts presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases